巴瑞替尼治疗难治性类风湿关节炎有效性和安全性的研究

Efficacy and Safety of Baricitinib in the Treatment of Difficult-To-Treat Rheumatoid Arthritis

目的探讨巴瑞替尼治疗难治性类风湿关节炎的有效性和安全性。方法选取2022年01月—2022年07月在苏州大学附属第一医院风湿科就诊的使用巴瑞替尼的30例难治性类风湿关节炎患者,研究患者治疗前后DAS-28改善幅度及治疗期间不良反应发生情况。结果(1)在第12周时,在30例接受巴瑞替尼治疗的患者中,有12例(40.0%)患者达疾病缓解状态。(2)与基线比较,第12周的DAS-28明显改善(P<0.001)。(3)用药12周后出现2例上呼吸道感染,症状轻微。结论巴瑞替尼在改善难治性类风湿关节炎患者的临床症状方面效果显著,未见明显不良反应。

Objective To investigate the efficacy and safety of Baricitinib in treatment of difficult-to-treat rheumatoid arthritis(D2T RA).Methods A total of 24 patients with D2T RA who received Baricitinib in the Department of Rheumatology,The First Affiliated Hospital of Soochow University from January 2022 to July 2022 were selected to compare the improvement of DAS-28 before and after treatment and the occurrence of adverse reactions during treatment.Results(1)At 12 weeks,12(40.0%)of the 30 patients treated with Baricitinib achieved remission.(2)DAS-28 at week 12 was significantly improved compared with baseline(P<0.001).(3)After 12 weeks of treatment,2 patients developed upper respiratory tract infection with mild symptoms.Conclusion Baricitinib is effective in improving clinical symptoms in patients with D2T RA and no obvious adverse reactions were observed.